Pain, Chronic Clinical Trial
Official title:
Apply the Pharmacodynamic Model of Peripheral Oxytocin Action to a Multimodal Stimulus That Increases (Heat) or Decreases (Vibration) Pain Perception
This is a study of participants that will receive an intravenous (IV) infusion of oxytocin (naturally occurring hormone that is made in the brain). In this study healthy volunteers are recruited. Each study participant will have an IV catheter placed. After placement of the IV catheter oxytocin will be given by IV infusion of oxytocin or placebo (inactive solution). The investigators will perform some tests to evaluate how oxytocin changes perceptions on the skin. The investigators will study a painful perception by placing a probe on the skin and heating it to 116.6 degrees Fahrenheit for 30 seconds and a vibratory stimulus will be applied to the forearm with vibration begun at a 1 kHz frequency and decreased at a rate of 25 Hz/sec until the subject first perceives the vibration. Each study participant will score any pain that is experienced on a 0 to 10 scale and will report when the vibration is detected. Each participant will receive oxytocin and placebo in a random order and will be blinded to group they are receiving.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Male or female > 18 and < 75 years of age, Body Mass Index (BMI) <40. 2. Generally in good health as determined by the Principal Investigator based on prior medical history, American Society of Anesthesiologists physical status 1 or 2. 3. For healthy volunteers, normal blood pressure (systolic 90-140 mmHg; diastolic 50-90 mmHg) resting heart rate 45-100 beats per minute) without medication. 4. Female subjects of child-bearing potential and those < 1 year post-menopausal, must be practicing highly effective methods of birth control such as hormonal methods (e.g., combined oral, implantable, injectable, or transdermal contraceptives), double barrier methods (e.g., condoms, sponge, diaphragm, or vaginal ring plus spermicidal jellies or cream), or total abstinence from heterosexual intercourse for a minimum of 1 full cycle before study drug administration. Exclusion Criteria: 1. Hypersensitivity, allergy, or significant reaction to any ingredient of Pitocin® 2. Any disease, diagnosis, or condition (medical or surgical) that, in the opinion of the Principal Investigator, would place the subject at increased risk (active gynecologic disease in which increased tone would be detrimental e.g., uterine fibroids with ongoing bleeding), compromise the subject's compliance with study procedures, or compromise the quality of the data 3. Women who are pregnant (positive result for serum pregnancy test at screening visit), women who are currently nursing or lactating, women that have been pregnant within 2 years 4. Subjects with neuropathy, chronic pain, diabetes mellitus, or taking benzodiazepines or pain medications on a daily basis. |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest Baptist Health | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Heat pain with vibration | Pain at the end of 30 sec of heating the skin to 47 degrees C with simultaneous vibration will be determined. Pain will be measured using a verbal Pain Scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to WORST PAIN IMAGINABLE. | Baseline before infusion | |
Primary | Heat pain with vibration | Pain at the end of 30 sec of heating the skin to 47 degrees C with simultaneous vibration will be determined. Pain will be measured using a verbal Pain Scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to WORST PAIN IMAGINABLE. | 5 minutes post infusion initiation | |
Primary | Heat pain with vibration | Pain at the end of 30 sec of heating the skin to 47 degrees C with simultaneous vibration will be determined. Pain will be measured using a verbal Pain Scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to WORST PAIN IMAGINABLE. | 15 minutes post infusion initiation | |
Primary | Heat pain with vibration | Pain at the end of 30 sec of heating the skin to 47 degrees C with simultaneous vibration will be determined. Pain will be measured using a verbal Pain Scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to WORST PAIN IMAGINABLE. | 30 minutes post infusion initiation | |
Secondary | Heat pain without vibration | Pain at the end of 30 sec of heating the skin to 47 degrees C will be determined. Pain will be measured using a verbal Pain Scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to WORST PAIN IMAGINABLE. | Baseline | |
Secondary | Heat pain without vibration | Pain at the end of 30 sec of heating the skin to 47 degrees C will be determined. Pain will be measured using a verbal Pain Scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to WORST PAIN IMAGINABLE. | 5 minutes post infusion initiation | |
Secondary | Heat pain without vibration | Pain at the end of 30 sec of heating the skin to 47 degrees C will be determined. Pain will be measured using a verbal Pain Scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to WORST PAIN IMAGINABLE. | 15 minutes post infusion initiation | |
Secondary | Heat pain without vibration | Pain at the end of 30 sec of heating the skin to 47 degrees C will be determined. Pain will be measured using a verbal Pain Scale 0-10. 0 is equivalent to NO PAIN and 10 is equivalent to WORST PAIN IMAGINABLE. | 30 minutes post infusion initiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
Recruiting |
NCT05037682 -
Pain and Opioid Management in Older Adults
|
N/A | |
Completed |
NCT04080037 -
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
|
N/A | |
Recruiting |
NCT05382962 -
iCanCope With Post-Operative Pain (iCanCope PostOp)
|
N/A | |
Recruiting |
NCT04285112 -
SPRINT: Signature for Pain Recovery IN Teens
|
||
Active, not recruiting |
NCT04850079 -
EHR Precision Drug Treatment in Neonates
|
||
Completed |
NCT03271151 -
Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT03272139 -
Interscalene Block Versus Superior Trunk Block
|
Phase 4 | |
Completed |
NCT03886142 -
Platelet Rich Plasma Versus Radio Frequency for Chronic Knee Arthritis
|
N/A | |
Recruiting |
NCT05761392 -
APP-based Precise Management System of Chronic Intractable Pain
|
N/A | |
Recruiting |
NCT05877157 -
Pain AND Opioids After Surgery
|
||
Completed |
NCT03947749 -
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
|
||
Completed |
NCT03280017 -
Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain
|
Phase 4 | |
Recruiting |
NCT04874038 -
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
|
Phase 3 | |
Completed |
NCT04280796 -
Changes in Affective Pain Processing in Human Volunteers
|
N/A | |
Withdrawn |
NCT05125978 -
Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain
|
Phase 2 | |
Not yet recruiting |
NCT04328805 -
Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome.
|
Phase 4 | |
Completed |
NCT04976738 -
A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain
|
Phase 1/Phase 2 | |
Completed |
NCT04089618 -
Meditation Based Lifestyle Modification in Chronic Pain
|
N/A | |
Recruiting |
NCT05699837 -
Alpha Entrainment for Pain and Sleep (Extension)
|
N/A |